CY1106070T1 - Πολυμορφισμοι στο γονιδιο c μεταφορας οργανικου ανιοντος ανθρωπου (oatp-c) - (organic anion transporter c gene) - Google Patents
Πολυμορφισμοι στο γονιδιο c μεταφορας οργανικου ανιοντος ανθρωπου (oatp-c) - (organic anion transporter c gene)Info
- Publication number
- CY1106070T1 CY1106070T1 CY20061100280T CY061100280T CY1106070T1 CY 1106070 T1 CY1106070 T1 CY 1106070T1 CY 20061100280 T CY20061100280 T CY 20061100280T CY 061100280 T CY061100280 T CY 061100280T CY 1106070 T1 CY1106070 T1 CY 1106070T1
- Authority
- CY
- Cyprus
- Prior art keywords
- gene
- organic anion
- anion transporter
- polymorphims
- oatp
- Prior art date
Links
- 102000007990 Organic Anion Transporters Human genes 0.000 title 2
- 108010089503 Organic Anion Transporters Proteins 0.000 title 2
- 108090000623 proteins and genes Proteins 0.000 title 2
- 101100533800 Homo sapiens SLCO1B1 gene Proteins 0.000 abstract 4
- 102100027233 Solute carrier organic anion transporter family member 1B1 Human genes 0.000 abstract 2
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 abstract 1
- 239000000463 material Substances 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 102000054765 polymorphisms of proteins Human genes 0.000 abstract 1
- 229920001184 polypeptide Polymers 0.000 abstract 1
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 1
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6813—Hybridisation assays
- C12Q1/6816—Hybridisation assays characterised by the detection means
- C12Q1/6825—Nucleic acid detection involving sensors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6813—Hybridisation assays
- C12Q1/6834—Enzymatic or biochemical coupling of nucleic acids to a solid phase
- C12Q1/6837—Enzymatic or biochemical coupling of nucleic acids to a solid phase using probe arrays or probe chips
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6844—Nucleic acid amplification reactions
- C12Q1/6858—Allele-specific amplification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
Abstract
Αυτή η εφεύρεση αναφέρεται σε πολυμορφισμούς στο ανθρώπινο γονίδιο OATPC και σε αντίστοιχα νέα αλληλικά πολυπεπτίδια που κωδικοποιούνται από αυτούς. Η εφεύρεση επίσης αναφέρεται σε μεθόδους και υλικά για την ανάλυση της αλληλικής ποικιλομορφίας στο γονίδιο OATPC, και στη χρήση του πολυμορφισμού OATPC στην αντιμετώπιση ασθενειών με μεταφερόμενα διά του OATPC φάρμακα όπως οι στατίνες.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US22690900P | 2000-08-23 | 2000-08-23 |
Publications (1)
Publication Number | Publication Date |
---|---|
CY1106070T1 true CY1106070T1 (el) | 2011-06-08 |
Family
ID=22850936
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CY20061100280T CY1106070T1 (el) | 2000-08-23 | 2006-02-28 | Πολυμορφισμοι στο γονιδιο c μεταφορας οργανικου ανιοντος ανθρωπου (oatp-c) - (organic anion transporter c gene) |
Country Status (8)
Country | Link |
---|---|
US (2) | US20020090622A1 (el) |
EP (2) | EP1589115A3 (el) |
JP (1) | JP2002330758A (el) |
AT (1) | ATE311476T1 (el) |
CY (1) | CY1106070T1 (el) |
DE (1) | DE60115349T2 (el) |
DK (1) | DK1186672T3 (el) |
ES (1) | ES2252159T3 (el) |
Families Citing this family (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE60042220D1 (de) | 1999-09-21 | 2009-06-25 | Chugai Pharmaceutical Co Ltd | Verwendung vom transportergen oatp-c zur screening von testsubstanzen |
GB0213580D0 (en) * | 2002-06-13 | 2002-07-24 | Astrazeneca Ab | Methods |
GB0317592D0 (en) * | 2003-07-26 | 2003-08-27 | Astrazeneca Ab | Method |
EP1784504A2 (en) * | 2004-07-21 | 2007-05-16 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Oatp-c gene c463a polymorphism underlies variable response of statin therapy |
FR2877013A1 (fr) | 2004-10-27 | 2006-04-28 | Assist Publ Hopitaux De Paris | Indentification d'une mutation de jak2 impliquee dans la polyglobulie de vaquez |
US20080280843A1 (en) * | 2006-05-24 | 2008-11-13 | Van Bilsen Paul | Methods and kits for linking polymorphic sequences to expanded repeat mutations |
EP2257646A1 (en) | 2008-02-29 | 2010-12-08 | ISIS Innovation Limited | Diagnostic methods |
US9817001B2 (en) | 2008-05-27 | 2017-11-14 | Boston Heart Diagnostics Corporation | Methods for determining LDL cholesterol treatment |
US8470541B1 (en) | 2008-09-27 | 2013-06-25 | Boston Heart Diagnostics Corporation | Methods for separation and immuno-detection of biomolecules, and apparatus related thereto |
EP2267153A1 (en) | 2009-05-26 | 2010-12-29 | Université Claude Bernard Lyon 1 | Identification of netrin-1 receptor unc5c gene mutation in solid cancers |
EP2766728B1 (en) | 2011-10-13 | 2017-09-06 | Boston Heart Diagnostics | Compositions and methods for treating and preventing coronary heart disease |
WO2014068072A1 (en) | 2012-10-31 | 2014-05-08 | Institut Gustave-Roussy | Identification, assessment and therapy of essential thrombocythemia with resistance to jak2 inhibitors |
US9828624B2 (en) | 2013-07-24 | 2017-11-28 | Boston Heart Diagnostics Corporation | Driving patient compliance with therapy |
WO2016081471A1 (en) | 2014-11-17 | 2016-05-26 | Boston Heart Diagnostic Corporation | Cardiovascular disease risk assessment |
JP7067896B2 (ja) * | 2017-10-27 | 2022-05-16 | シスメックス株式会社 | 品質評価方法、品質評価装置、プログラム、および記録媒体 |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20010006644A1 (en) * | 1997-07-31 | 2001-07-05 | David J. Bova | Combinations of hmg-coa reductase inhibitors and nicotinic acid and methods for treating hyperlipidemia once a day at night |
EP1141282A2 (en) * | 1998-08-07 | 2001-10-10 | Axys Pharmaceuticals, Inc. | Human anion transporter genes atnov |
-
2001
- 2001-08-10 US US09/925,731 patent/US20020090622A1/en not_active Abandoned
- 2001-08-17 AT AT01306983T patent/ATE311476T1/de active
- 2001-08-17 ES ES01306983T patent/ES2252159T3/es not_active Expired - Lifetime
- 2001-08-17 DK DK01306983T patent/DK1186672T3/da active
- 2001-08-17 EP EP05011183A patent/EP1589115A3/en not_active Withdrawn
- 2001-08-17 DE DE60115349T patent/DE60115349T2/de not_active Expired - Lifetime
- 2001-08-17 EP EP01306983A patent/EP1186672B1/en not_active Expired - Lifetime
- 2001-08-22 JP JP2001251461A patent/JP2002330758A/ja active Pending
-
2003
- 2003-10-31 US US10/698,808 patent/US20040235006A1/en not_active Abandoned
-
2006
- 2006-02-28 CY CY20061100280T patent/CY1106070T1/el unknown
Also Published As
Publication number | Publication date |
---|---|
ES2252159T3 (es) | 2006-05-16 |
DE60115349T2 (de) | 2006-08-10 |
US20040235006A1 (en) | 2004-11-25 |
EP1589115A3 (en) | 2006-05-31 |
ATE311476T1 (de) | 2005-12-15 |
US20020090622A1 (en) | 2002-07-11 |
EP1186672A2 (en) | 2002-03-13 |
EP1186672B1 (en) | 2005-11-30 |
EP1186672A3 (en) | 2002-09-25 |
DK1186672T3 (da) | 2006-03-06 |
EP1589115A2 (en) | 2005-10-26 |
JP2002330758A (ja) | 2002-11-19 |
DE60115349D1 (de) | 2006-01-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CY1106070T1 (el) | Πολυμορφισμοι στο γονιδιο c μεταφορας οργανικου ανιοντος ανθρωπου (oatp-c) - (organic anion transporter c gene) | |
CY1118467T1 (el) | Σκευασματα αντισωματων και πρωτεϊνων υψηλης συγκεντρωσης | |
CY1119029T1 (el) | Θεραπευτικη αντιμετωπιση συμπαγων εγκεφαλικων νεοπλασιων με ενα παραγωγο ραπαμυκινης | |
CY1120070T1 (el) | Μεθοδοi θεραπευτικης αγωγης με τη χρηση συζευγματων αντισωματος εναντι-erbb-μεϋτανσινοειδους | |
CY1120257T1 (el) | ΠΥΡΡΟΛΟ[2,3b]ΠΥΡΙΔΙΝ-4-ΥΛΑΜΙΝΕΣ ΚΑΙ ΠΥΡΡΟΛΟ[2,3b]ΠΥΡΙΜΙΔΙΝ-4-ΥΛΑΜΙΝΕΣ ΩΣ ΑΝΑΣΤΟΛΕΙΣ ΚΙΝΑΣΩΝ JANUS | |
CY1116385T1 (el) | Αντινοηματικη διαμορφωση της εκφρασης της απολιποπρωτεινης β | |
CY1120018T1 (el) | Θεραπεια του οικογενους μεσογειακου πυρετου με αντι-il-1b αντισωματα | |
LU92991I2 (fr) | Efmoroctocog alfa ou un produit biosimilaire conformément à l'article 10 (4) de la directive 2001/83/ce, tel que protégé par le brevet de base | |
CY1114397T1 (el) | Φαρμακευτικες συνθεσεις οι οποιες περιλαμβανουν βακτηρια τα οποια μειωνουν οξαλικα | |
CY1111225T1 (el) | Νεα πεπτιδια ως αναστολεις πρωτεασης νs3-σερινης ιου ηπατiτιδας c | |
PE20081392A1 (es) | Moleculas de enlace de lingo | |
CY1110177T1 (el) | Ω-καρβοξυαρυλο υποκατεστημενες διφαινυλουριες ως αναστολεις της raf κινασης | |
CY1112055T1 (el) | Συνθεσεις και μεθοδοι για την διαγνωση και θεραπευτικη αγωγη ογκου πνευμονα | |
ATE529442T1 (de) | Verbesserte humane interferon-moleküle und ihre verwendungen | |
CY1110416T1 (el) | Δικυκλικα παραγωγα ιμιδαζ-5-υλ-αμινης | |
CY1111371T1 (el) | Αντισωματα bag3 για χρηση σε ερευνα, διαγνωση και θεραπεια ασθενειων που σχετιζονται με κυτταρικο θανατο | |
DE602006007967D1 (de) | Gegen das gemeinsame epitop von mutierten p53 gerichtete humane synthetische einzelkettenantikörper und anwendungen davon | |
DK1490490T3 (da) | Antisense IAP--nukleobase-oligomerer og anvendelser deraf | |
CY1106133T1 (el) | Αγωνιστες υποδοχεα 2 παραγοντα απελευθερωσης κορτικοτροπινης | |
DE60235005D1 (de) | Nachweis der instabilität von mikrosatelliten und | |
ES2530670T3 (es) | Anticuerpo anti-FGF23 y composición farmacéutica que comprende el mismo | |
GB9924957D0 (en) | Novel treatment | |
PE20021098A1 (es) | ANTICUERPOS ESPECIFICOS DE CD44v6 | |
DK1667711T3 (da) | Forebyggende cancervaccine baseret på BORIS (Brother of Regulator of Imprinted Sites)-molekyle | |
NO20053903D0 (no) | Nukleotidlipidesterderivater. |